MedPath

The effect of adding buspirone to SSRIs in the treatment of obsessive-compulsive disorder

Phase 3
Recruiting
Conditions
Obsessive Compulsive Disorder.
Obsessive-compulsive disorder
Registration Number
IRCT20180303038927N1
Lead Sponsor
Qazvin University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Yale Brown criteria scale for Obsessive Compulsive Disorder (OCD) > 21 score
Patients will be selected according to the demographic information as: age/gender/marital status/education/job/onset age of illness/previous treatment/
age should be 18-60
The other psychiatric disease should not be existed
opioid/stimulant/should not be existed
Liver and Kidney diseases should not be existed

Exclusion Criteria

Yale Brown Scale below 21 scale
Opioid use disorders
Stimulant use disorders
Liver Failure
Kidney Failure

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group 6 weeks after the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group in the end of the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group with Placebo Group six weeks after the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group with Placebo Group in the end of the treatment. Method of measurement: Yale Brown Scale.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath